From Concept to Approval: Evaluating Technical Risk Before You Invest

In drug development, brilliant science alone doesn’t secure regulatory approval—or commercial success. 
Technical risks related to Chemistry, Manufacturing, and Controls (CMC), regulatory pathways, and manufacturing scalability are often the silent killers of otherwise promising programs. 

For investors evaluating biotech opportunities, understanding how technical risk evolves from concept to approval is critical to making informed, strategic investment decisions. 

Early Development (Discovery Through Preclinical) 

Key Risks: 

• No defined regulatory starting materials or synthetic route 

• Lack of early formulation feasibility 

• Uncharacterized impurities and degradation pathways 

• Overreliance on non-GMP materials in toxicology studies 

What to Evaluate: 

• Is there a plausible, scalable drug substance and drug product strategy? 

• Has there been proactive thinking about regulatory expectations (e.g., FDA, EMA)? 

• Are impurities and degradation risks already being assessed, even if informally? 

Investor Tip: 
Early investment rounds must account for the technical leap required to move from proof-of-concept to IND-enabling development. 

IND-Enabling Stage 

Key Risks: 

• Insufficiently phase-appropriate CMC packages for IND submission 

• Gaps in analytical method validation 

• Weak justification of starting materials under ICH Q11 

• Unclear stability data to support clinical shelf-life 

What to Evaluate: 

• Has the company planned for and generated sufficient CMC data to meet FDA IND expectations? 

• Are analytical methods fit for purpose to release clinical materials and perfrom stability studies? 

• Is the supply chain secured for Phase 1 manufacturing? 

Investor Tip: 
An IND filing is a major milestone—but it’s also where programs can be delayed if CMC or regulatory diligence was weak early on. 

Clinical Development (Phase 1 to Phase 3) 

Key Risks: 

• Inability to scale manufacturing processes reliably 

• Failure to bridge preclinical and clinical lots properly 

• Analytical methods insufficient for commercial validation 

• Lack of process validation planning for pivotal studies 

What to Evaluate: 

• Has the company begun process optimization and scale-up activities aligned with Phase 3 and commercialization? 

• Are there defined Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs)? 

• Is there evidence of ongoing dialogue with regulators (e.g., pre-IND, EOP2 meetings)? 

Investor Tip: 
Phase 2 success doesn’t mean regulatory readiness. CMC development must advance in parallel with clinical programs—not afterward. 

Pre-Approval Stage (Pre-NDA/BLA Submission) 

Key Risks: 

• Missing validation data for drug substance and drug product 

• Inadequate stability data for the proposed shelf-life 

• Manufacturing facilities not ready for Pre-Approval Inspections (PAIs) 

What to Evaluate: 

• Are process performance qualification (PPQ) runs completed or scheduled? 

• Are commercial-scale stability studies available and robust? 

• Are quality systems and documentation inspection-ready? 

Investor Tip: 
Programs that rush to file without robust CMC packages often face major regulatory delays—or costly Complete Response Letters (CRLs). 

Technical Risk vs. Business Risk: Understanding the Balance 

Strong technical foundations de-risk not only the regulatory path but the commercial viability of the asset. 

Final Thoughts 

Early diligence focused only on clinical promise misses a critical dimension: Can the product actually be made, scaled, and approved?  Savvy investors evaluate technical risk early—before it compounds into bigger problems later. 

At DSI, we work with investors and sponsors to perform deep technical risk assessments across CMC, regulatory strategy, and manufacturing readiness. 
If you're evaluating a biotech investment or preparing for a major raise, we can help you identify hidden risks—and show you how to fix them before they cost you.